Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.14 – $0.36
43% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $149.2K | $97.6K | $238.9K | $467.7K | $973.0K | $1.5M | $2.1M | $2.1M |
| Cost of revenue | $0 | $70.1K | $21.6K | $32.3K | $50.4K | $53.7K | $181.7K | $0 |
| Gross profit | $149.2K | $27.5K | $217.3K | $435.4K | $922.6K | $1.4M | $2.1M | $2.1M |
| Gross margin | 100.0% | 28.1% | 91.0% | 93.1% | 94.8% | 96.5% | 100.0% | 100.0% |
| R&D | $0 | $129.7K | $465.9K | $974.0K | $2.3M | $3.0M | $4.5M | $4.8M |
| Operating income | −$961.7K | −$1.8M | −$3.4M | −$2.2M | −$12.4M | −$8.3M | −$4.7M | −$6.5M |
| EBITDA | −$973.4K | −$1.7M | −$3.4M | −$2.5M | −$12.8M | −$8.7M | −$5.1M | −$6.9M |
| Net income | −$1.9M | −$1.7M | −$2.8M | −$6.6M | −$14.1M | −$9.0M | −$4.8M | −$7.0M |
| Net margin | -1243.0% | -1781.0% | -1179.4% | -1409.8% | -1450.8% | -604.1% | -224.9% | -339.2% |
| EPS (diluted) | -0.01 | -0.01 | -0.01 | -0.01 | -0.06 | -0.04 | -0.02 | -0.03 |
Annual figures · source: Financial Modeling Prep
ARCHER MATERIALS LTD
No one on the platform currently holds ARRXF.
No tracked institution reports a position in ARRXF as of their last filing.
| Execution date | Ratio |
|---|---|
| 2018-03-06 | 1-for-6.5536615reverse |
| 2014-04-15 | 1-for-10reverse |
No one on the platform has traded ARRXF yet.
| $16M |
| — |
| NPNZFNippon Antenna Co.,Ltd. | $8.65 | +0.00% | $90M | — |
| PONGFAtari S.A. | $20.00 | +0.00% | $45M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 32.5× sales vs its 54.2× historical median P/S.
Fair value ≈ $0.39 · price $0.23 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$ARRXF Wird der morgen in Australien auch hochgehen wie Sealsq?
View on StockTwits ↗$ARRXF one morning soon this will open up over $3.50 and you will not be in!!!!
View on StockTwits ↗$ARRXF https://youtu.be/9Cyx3KUQpjo?si=aaS1Yfb4CYcmJBaW
View on StockTwits ↗$ARRXF Archer has officially confirmed they are 100% on track for their anticipated working QUBIT demonstration this year (2026) They are moving beyond early-stage validation into repeatable design and testing now.
View on StockTwits ↗$ARRXF don't know if anyone saw the investor call but it's worth going back and listening too. production rolling out in a few months, the end of the year is going to be absolutely bananas.
View on StockTwits ↗$QBTS ----QUANTUM stocks soaring including $QBTS, $RGTI, $IONQ.....WILL $ARRXF have a large percentage upmove ? Check it out.
View on StockTwits ↗$ARRXF all quantum stocks move with good news for the sector except this. So I hold, not adding. They need to do a secondary listing..
View on StockTwits ↗$ARRXF just found this. What yalls thoughts and why?
View on StockTwits ↗$ARRXF looking to fill order at .20 it grts there but the brokerage isn't catching it ?
View on StockTwits ↗$ARRXF would like to fill a order at . 21 cent the .22 is notable stable
View on StockTwits ↗$ARRXF News yesterday Archer Materials advanced technical work toward a demonstrator quantum qubit device, including progress on qubit readout and efforts to scale carbon material growth for wafer-scale device fabrication. The company also completed the first phase of its quantum machine learning fraud detection project and is targeting a full prototype by end of 2026. Notably, Archer recorded positive net operating cash flow of $139,000 for the quarter and ended March with no debt. Biochip Update: The blood potassium Biochip program reached alpha-prototype stage at clinical standard, creating the basis for beta-prototype development later this year ahead of clinical trials and commercial negotiations.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.